tbuckley/cabot-search huggingface dataset:
Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases
Authors: Francesca Conti, Saul Oswaldo Lugo-Reyes, Lizbeth Blancas Galicia, Jianxin He, Güzide Aksu, Edgar Borges de Oliveira, Caroline Deswarte, Marjorie Hubeau, Neslihan Karaca, Maylis de Suremain, Antoine Guérin, Laila Ait Baba, Carolina Prando, Gloria G. Guerrero, Melike Emiroglu, Fatma Nur Öz, Marco Antonio Yamazaki Nakashimada, Edith Gonzalez Serrano, Sara Espinosa, Isil Barlan, Nestor Pérez, Lorena Regairaz, Héctor Eduardo Guidos Morales, Liliana Bezrodnik, Daniela Di Giovanni, Ghassan Dbaibo, Fatima Ailal, Miguel Galicchio, Matias Oleastro, Jalel Chemli, Silvia Danielian, Laura Perez, Maria Claudia Ortega, Susana Soto Lavin, Joseph Hertecant, Ozden Anal, Nadia Kechout, Eman Al-Idrissi, Gehad ElGhazali, Anastasia Bondarenko, Liudmyla Chernyshova, Peter Ciznar, Rose-Marie Herbigneaux, Aminata Diabate, Stéphanie Ndaga, Barik Konte, Ambre Czarna, Mélanie Migaud, Sigifredo Pedraza-Sánchez, Mussaret Bano Zaidi, Guillaume Vogt, Stéphane Blanche, Imen Benmustapha, Davood Mansouri, Laurent Abel, Stéphanie Boisson-Dupuis, Nizar Mahlaoui, Ahmed Aziz Bousfiha, Capucine Picard, Ridha Barbouche, Saleh Al-Muhsen, Francisco J. Espinosa-Rosales, Necil Kütükçüler, Antonio Condino-Neto, Jean-Laurent Casanova, Jacinta Bustamante
Journal: Journal of Allergy and Clinical Immunology (2016)
Finalists are announced for The BMJ Awards 2016
Authors: Zosia Kmietowicz
Journal: BMJ (2016)

The clinical leadership teams that have made the shortlist for The BMJ Awards 2016 cover a range of subjects, including reconfiguring ophthalmology services in Leeds, improving heart health in Bradford, and restructuring diabetes care in Portsmouth to ensure that patients access the right specialist care.

Now in their eighth year, the awards have …
Results of a randomized phase II study of irofulven in hormone-refractory prostate cancer patients that have failed first-line docetaxel treatment
Authors: E. R. Berger, T. Ciuleanu, L. Hart, K. N. Chi, J. Alexandre, S. Oudard, C. Kahatt, G. Weems, E. Cvitkovic, J. R. MacDonald
Journal: Journal of Clinical Oncology (2007)

5068 Background: Currently, no available treatments demonstrate an increase in survival for patients (pts) with hormone- refractory prostate cancer (HRPC) who have failed treatment with docetaxel-based regimens. Previous monotherapy and combination Phase I/II trials with irofulven (IROF) have shown antitumor effects in pts with HRPC, including those with resistance to docetaxel. A randomized phase II study was undertaken in HRPC pts with documented resistance to docetaxel to evaluate the efficacy and safety of IROF regimens compared to mitoxantrone (MITOX). Methods: Pts with metastatic HRPC with documented progression by RECIST or PSA Working Group criteria during or within 3 months of prior docetaxel were randomized to 1 of 3 arms in a 2:2:1 ratio: Arm A: IROF (0.45 mg/kg, Day [D]1, 8 every [q] 3 weeks [w]) and prednisone (PRED; 10 mg qd); Arm B: IROF (0.4 mg/kg D1, 15), capecitabine (CAPE; 2,000 mg/m 2 D1–15 q4w) and PRED; Arm C: MITOX (12 mg/m 2 q3w) and PRED. Pts were stratified by baseline pain status. Efficacy endpoints included time to progression (TTP), overall survival (OS), and response. Results: Enrollment of 134 treated pts was completed as of Jan 2006 (Arm A/B/C: 53/54/27). Median age: 64/66/63 years, median KPS: 80/90/80, median baseline PSA (ng/mL): 144/136/243, disease-related pain at baseline: 65%/57%/59%, and median number of metastatic sites: 1/1/2. Median pre-study PSA doubling time (days) was 42/44/50. Efficacy: As of Jan 2007, median OS (mos) was 10.1/9.5/7.4 in Arms A/B/C (based on 73% of pt deaths). Preliminary median TTP (mos) was 2.2/3.8/1.8, based mainly on PSA progression. PSA and RECIST responses were 10%/22%/0% and 10%/10%/13%, respectively. Safety: Treatment was well tolerated in all arms. The most frequent Grade 3–4 toxicities (% pts) were asthenia (8%/15%/0%), and vomiting (4%/11%/0%). Grade 3–4 hematological events included neutropenia (22%/15%/61%) and thrombocytopenia (23%/21%/4%). Conclusions: Results to date indicate longer survival, longer TTP, and greater PSA response for IROF/PRED and IROF/CAPE/PRED compared to MITOX/PRED. Based on these data, a larger randomized trial of irofulven in docetaxel resistant HRPC patients is warranted. No significant financial relationships to disclose.
LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first-line chemotherapy.
Authors: Luca Faloppi, Michela Del Prete, Mario Scartozzi, Daniele Santini, Maristella Bianconi, Riccardo Giampieri, Stefano Cascinu
Journal: Journal of Clinical Oncology (2015)

313 Background: Previous data suggested that LDH serum levels may be associated with tumour hypoxia and VEGFA and VEGFR-1 over-expression. LDH may then represent an indirect marker of activated tumour neo-angiogenesis and worse prognosis in many tumour types. In our analysis, we analyzed the role of LDH serum levels in predicting clinical outcome for biliary tract cancer patients treated with first-line cisplatin and gemcitabine chemotherapy, to individuate a potentially reliable and easy to use marker for patients stratification. Methods: 71 advanced biliary tract cancer patients treated with cisplatin and gemcitabine in first-line chemotherapy were available for our analysis. For all patients, LDH values were collected within one month before treatment beginning. We chose the laboratory cut-off (Upper Normal Rate, UNR) as LDH cut-off value (450 U/l) and then we divided the patients into two groups (A and B, below and above the UNR respectively). Survival distribution was estimated by the Kaplan-Meier method. Disease control rate (DCR) was assessed with chi-square test. A significant level of 0.05 was chosen to assess the statistical significance. Results: Patients in group A (46 patients) and B (25 patients) proved homogeneous for all clinical characteristics analyzed. Median progression free survival (PFS) was 3.97 months and 1.8 months respectively in group A (patients with LDH level below the UNR) and in group B (patients with LDH level above the UNR), p=0.0064 (HR=2.07, 95%CI: 1.07-3.99). Median overall survival (OS) was 9.24 months and 2.55 months in group A and B respectively, p&lt;0.0001 (HR=2.93; 95%CI: 1.37-6.27). DCR was 65% in group A vs. 21% in group B (p=0.004). Conclusions: Our observations seem to suggest a prognostic role of LDH in biliary tract cancer patients. Our findings showing an improved PFS and DCR in patients with low LDH serum levels also suggest a possible predictive role in patients treated with a cisplatin and gemcitabine regimen as first-line chemotherapy. After further confirmation in larger trial, these results may be relevant for a better patients stratification and selection.
Abstract 11491: Differences in the Development of Restenosis Over Time for Various Drug-Eluting Stents
Authors: Kosei Tanaga
Journal: Circulation (2014)

Objective: This study aims to compare the efficacy of sirolimus-eluting stents (SES), paclitaxel-eluting stents (PES), zotarolimus-eluting stents (ZES), and everolimus eluting stents (EES) via sequential angiographic follow-up and to reveal the development of restenosis over time. Methods: Patients were randomized to receive SES, PES, ZES, or EES, and follow-up angiography was performed at 6, 12 and 24months after percutaneous coronary intervention. Results: The baseline clinical characteristics of the patients and the coronary lesions are shown in (Table 1). In all groups, mean minimal lumen diameter decreased slightly during the 2-year period after the procedure (Figure 1). Compared with the SES group, the PES and the ZES groups showed greater late loss (LL) within 1 year. However, the SES group showed significantly greater LL compared with the other drug-eluting stents (DES) between 1 and 2 years (Figure 2). Conclusion: Serial angiographic analysis revealed differences in the rate of restenosis development over time for various DES. As DES are comprised of many components (metallic platform, alloy, drug and polymer), the progression of LL can be complex and affected by different factors.
Surgeon specialization and patient satisfaction with breast cancer treatment
Authors: J. F. Waljee, S. T. Hawley, A. K. Alderman, M. Morrow, S. J. Katz
Journal: Journal of Clinical Oncology (2007)

11012 Background: Experience and practice setting vary greatly among surgeons who treat patients with breast cancer. Yet, little is known about how these factors influence patient outcomes such as patient satisfaction with aspects of care. Methods: All women with DCIS and a 20% random sample of women with invasive breast cancer diagnosed in 2002 and reported to the Detroit and Los Angeles metropolitan SEER registries were identified and surveyed shortly after receipt of surgical treatment. Attending surgeons were identified primarily using pathology reports and mailed a survey. The final sample contained complete dyad information for 64.6% of patients (n=1,539) and 69.7% of surgeons (n=318). Logistic regression was used to examine the associations between surgeon specialization (% of practice devoted to breast disease) and treating hospital cancer program status (no program, American College of Surgeons approved cancer program, or NCI cancer center) with four domains of patient satisfaction: 1) the surgical decision, 2) decision-making process, 3) surgeon-patient relationship, and 4) surgeon-patient communication, adjusting for patient and surgeon demographics and disease stage. Results: 34.5%, 32.5% and 33.0% of patients were treated by surgeons who devoted &lt;30% (low volume), 30%-60% (medium volume), and &gt;60% (high volume) of their practice to breast disease. Compared to patients who were treated by low volume surgeons, patients treated by medium or high volume surgeons were more satisfied with the decision making process (medium volume: OR=1.2, 95%CI 0.8–1.7, high volume: OR=1.8, 95% CI 1.1- 2.8, p=0.036) and more satisfied with the surgeon-patient relationship (medium volume: OR=1.1, 95% CI 0.7 - 1.7, high volume: OR=2.1, 95% CI 1.1–3.7, p=0.053). Similar trends were observed for the other domains of satisfaction. Treatment setting was not associated with patient satisfaction after controlling for other factors. Conclusions: Surgeon specialization, but not treatment setting, was associated with patient satisfaction. Examining the processes underlying these associations could inform strategies to improve the quality of breast cancer care. No significant financial relationships to disclose.
Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy
Authors: Yaw A. Nyame, Adam B. Murphy, Diana K. Bowen, Gregory Jordan, Ken Batai, Michael Dixon, Courtney M.P. Hollowell, Stephanie Kielb, Joshua J. Meeks, Peter H. Gann, Virgilia Macias, Andre Kajdacsy-Balla, William J. Catalona, Rick Kittles
Journal: Journal of Clinical Oncology (2016)

Lower serum vitamin D levels have been associated with an increased risk of aggressive prostate cancer. Among men with localized prostate cancer, especially with low- or intermediate-risk disease, vitamin D may serve as an important biomarker of disease aggression. The aim of this study was to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) levels.This cross-sectional study was carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension. Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy.Eighty-seven men (45.8%) in this cohort demonstrated adverse pathology at radical prostatectomy. The median age in the cohort was 64.0 years (interquartile range, 59.0 to 67.0). On univariate analysis, men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (22.7 v 27.0 ng/mL, P = .007) compared with their counterparts. On multivariate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was associated with increased odds of adverse pathology (odds ratio, 2.64; 95% CI, 1.25 to 5.59; P = .01).Insufficiency/deficiency of serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.
Risk Factors for Targeted Fungal and Mycobacterial Infections in Patients Taking Tumor Necrosis Factor Inhibitors
Authors: Elizabeth Salt, Amanda T. Wiggins, Mary Kay Rayens, Moises A. Huaman, David Mannino, Philip Schwieterman, Scott A. Merkley, Allison R. Jones, Leslie J. Crofford
Journal: Arthritis & Rheumatology (2015)

Objective To identify predictors of the receipt of medical care, including the receipt of pre‐drug screening, for diagnostically targeted fungal or mycobacterial infections among patients prescribed a tumor necrosis factor inhibitor (TNFi). Methods We conducted a case–control study using deidentified patient health claims information from a data set representing a commercially insured US population of 15 million patients annually from January 1, 2007 to December 31, 2009. Descriptive statistics as well as a 2‐sample t ‐test, chi‐square test of association, Fisher's exact test, and multivariate logistic regression were used for data analysis. Results A total of 30,772 patients received a TNFi during the study period. Of these, 158 patients (0.51%) developed targeted fungal and/or mycobacterial infections (cases). The median number of infections per case was 1.0 (interquartile range 1.0–2.0). Tuberculosis was diagnosed in 61% of cases, followed by histoplasmosis in 60%, nontuberculous mycobacterial infections in 11%, coccidioidomycosis in 10%, unspecified fungal infection in 8%, blastomycosis in 4%, cryptococcal infection in 3%, and pneumocystosis in 2%. Compared to controls (n = 474), a higher proportion of cases were prescribed prednisone (55% versus 37%; P &lt; 0.001). Patients who were prescribed prednisone during the study period were twice as likely as those not taking prednisone to seek medical care attributable to a targeted fungal or mycobacterial infection (odds ratio 2.03; P &lt; 0.001). Conclusion Development of a targeted fungal or mycobacterial infection among patients taking a TNFi is rare. Concomitant use of prednisone predicted development of such infections.
Abstract 13681: Feasibility of Single-Beat Full-Volume Capture Real-Time Three-Dimensional Echocardiography for Quantification of Right Ventricular Volume: Validated by Cardiac Magnetic Resonance Imaging
Authors: Jing Ping Sun, Quan Bin Zhang, Rui Feng Gao, Feng Yan Lin, Xiao Rong Liu, Wei Sheng, Feng Liu, Cheuk-Man Yu
Journal: Circulation (2012)

article i nfo Background: The lack of an accurate noninvasive method for assessing right ventricular (RV) volume and function has been a major deficiency of two-dimensional (2D) echocardiography. The aim of our study was to test the feasibility of single-beat full-volume capture with real-time three-dimensional echo (3DE) imag- ing system for the evaluation of RV volumes and function validated by cardiac magnetic resonance imaging (CMRI). Methods: Sixty-one subjects (16 normal subjects, 20 patients with hypertension, 16 patients with pulmonary heart disease and 9 patients with coronary heart disease) were studied. RV volume and function assessments using 3DE were compared with manual tracing with CMRI as the reference method. Results: Fifty-nine of 61 patients (96.7%; 36 male, mean age, 62 ± 15 years) had adequate three-dimensional echocardiographic data sets for analysis. The mean RV end diastolic volume (EDV) was 105 ± 38 ml, end-systolic volume (ESV) was 60 ± 30 and RV ejection fraction (EF) was 44 ± 11% by CMRI; and EDV 103 ± 38 ml, ESV 60 ± 28 ml and RV EF 41 ± 13% by 3DE. The correlations and agreements between mea- surements estimated by two methods were acceptable. Conclusion: RV volumes and function can be analyzed with 3DE software in most of subjects with or without heart diseases, which is able to be estimated with single-beat full-volume capture with real-time 3DE com- pared with CMRI.
Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)
Authors: R. Jakesz, H. Samonigg, R. Greil, M. Gnant, M. Schmid, W. Kwasny, E. Kubista, B. Mlineritsch, C. Tausch, M. Stierer
Journal: Journal of Clinical Oncology (2005)

527 Background: ABCSG Trial 6 demonstrated that postmenopausal women with pT1–3a, any N, M0 hormone receptor-positive early stage breast cancer (EBC) randomized to 2 years tamoxifen (TAM) in combination with aminoglutethimide (AG) 500 mg, followed by 3 years TAM (n=996), did not have an improved prognosis, when compared with patients treated with 5 years TAM (n=990). We present results from ABCSG-6a, an extended adjuvant trial of ABCSG-6, which investigates whether continuing treatment with anastrozole ('Arimidex') [ANA] will improve overall prognosis. Methods: Postmenopausal women who had received TAM in combination with AG (n=406), or TAM alone (n=450), were re-randomized to switch to ANA 1 mg/day or no treatment (NT) for a further 3 years. The primary endpoint was event-free survival. Local or regional relapse was confirmed histologically where possible. Differences between the treatment groups were assessed by log-rank test. Results: Tumors <1cm,1–2 cm, or > 2cm in diameter were found in 135, 402 and 319 patients, respectively. Of the 856 patients, 578 had N0 disease, 261 patients had 1–3 nodes and 17 patients had >4 nodes involved. 171 patients had a histological Grade 3 lesion and 685 patients had Grade 1, 2 or lobular carcinomas. At 5 years' median follow-up, 86 patients experienced local regional, distant metastases or contralateral breast cancer. Significantly fewer patients in the ANA group experienced disease recurrence compared with the NT group (30 vs 56 patients, respectively; hazard ratio 0.64; 95% confidence interval 0.41, 0.99; p=0.047). There was no statistically significant difference with respect to overall survival. Conclusions: Significantly fewer patients receiving ANA experienced disease relapse compared with placebo following 5 years of TAM with or without AG in postmenopausal women with EBC. Our results show that postmenopausal women who have completed 5 years of therapy with TAM with or without AG benefit from extended adjuvant therapy with ANA. No significant financial relationships to disclose.
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Authors: Omkar U. Kawalekar, Roddy S. O’Connor, Joseph A. Fraietta, Lili Guo, Shannon E. McGettigan, Avery D. Posey, Prachi R. Patel, Sonia Guedan, John Scholler, Brian Keith, Nathaniel W. Snyder, Ian A. Blair, Michael C. Milone, Carl H. June
Journal: Immunity (2016)
Once-weekly dosing of epoetin alfa are similar to three-times-weekly dosing to improve hemoglobin levels in chemotherapy patients: Results From multicenter prospective cohort study
Authors: J. Muñoz-Langa, O. Juan, S. Olmos, A. Albert, C. Molins, V. Carañana, D. Almenar, J. M. Campos, C. Bosch, V. Alberola
Journal: Journal of Clinical Oncology (2005)

8161 Background: to prospectively evaluate the effectiveness of two different epoetin alfa dosing to improve hemoglobin (Hb) levels in chemotherapy (CT) patients (pts). Methods: A total of 290 pts with nonmyeloid malignancies who received CT were included into this prospective, multicenter, open-label and nonrandomized controlled cohort study. A cohort of 190 pts received epoetin alfa 10,000 IU three-times weekly (t.i.w.) and a second cohort of 100 pts received 40,000 IU once weekly (q.w.). Epoetin alfa dose could be increased to 60,000 IU/w after 3 weeks depending on Hb response. The efficacy variables were hematopoietic response (defined as an increase in Hb ≥ 2 g/dL or achievement of a Hb level ≥ 12 g/dL); mean change in Hb level; rate of pts who needed increase epoetin alfa dose; number of treatment’s weeks and the rate of pts transfused. Multivariate analyses using a logistic and lineal regression model were performed to provide a measure of treatment effect adjusted for those variables that were reported as significantly different between both groups. Results: There were no significant differences in the demographic and baseline clinical characteristics between the two treatment groups except baseline endogenous EPO. In the multivariate analysis, no significant differences were found regarding to Hematopoietic response rate (69.9% vs 67.7% for t.i.w vs q.w. group; p=0.224); mean change in Hb (0.5 g/dL [95% CI 0.3–0.7] vs 0.6 g/dL [95% CI 0.3–0.9] for t.i.w vs q.w dosing; p=0.533) and the rate of pts transfused (8.2% vs 8.6% for t.i.w vs q.w group; p=0.774). Epoetin alfa dose was doubled in 34.9% of pts in t.i.w cohort versus 6.8% in q.w. cohort (p=0.0001). Mean number of weeks of epoetin alfa treatment was similar in both groups (7 w [95% CI 6.3–7.7] vs 6.5 w [95% CI 5.7–7.4] for t.i.w vs q.w dosing; p=0.095), although mean weeks with double dose was higher in t.i.w group (1.9 w [95% CI 1.4–2.5] than in q.w. gropu (0.3 w [95% CI 0.03–0.5] (p=0.0001). Conclusions: once-weekly 40.000 U of epoetin alfa is similar to 10.000 U three-times weekly to increase Hb levels but with a lower need of dose increased and, probably, with a better cost-effectiveness. No significant financial relationships to disclose.
Safety profile of single-dose dexamethasone premedication for paclitaxel.
Authors: B Parikh, S Khanolkar, S H Advani, B Dhabhar, M Chandra
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.7.2189 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8683256 Safety profile of single-dose dexamethasone premedication for paclitaxel. B ParikhxB ParikhSearch for articles by this author , S KhanolkarxS KhanolkarSearch for articles by this author , S H AdvanixS H AdvaniSearch for articles by this author , B DhabharxB DhabharSearch for articles by this author , M ChandraxM ChandraSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.7.2189 PDF "Safety profile of single-dose dexamethasone premedication for paclitaxel.." Journal of Clinical Oncology, 14(7), pp. 2189–2190© 1996 by American Society of Clinical Oncology